Medgenics Inc (NASDAQ:GNMX) – Analysts at Jefferies Group dropped their FY2019 EPS estimates for Medgenics in a research report issued on Wednesday, March 14th, Zacks Investment Research reports. Jefferies Group analyst M. Andrews now expects that the biotechnology company will post earnings of ($1.35) per share for the year, down from their previous forecast of ($1.26). Jefferies Group also issued estimates for Medgenics’ FY2020 earnings at ($1.71) EPS, FY2021 earnings at ($1.45) EPS and FY2022 earnings at ($1.49) EPS.
Medgenics (NASDAQ:GNMX) last announced its quarterly earnings data on Tuesday, March 13th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02.
Shares of NASDAQ GNMX opened at $1.83 on Friday. The stock has a market capitalization of $108.59, a price-to-earnings ratio of -2.20 and a beta of 1.03. Medgenics has a 1 year low of $0.98 and a 1 year high of $2.65.
An institutional investor recently raised its position in Medgenics stock. Renaissance Technologies LLC boosted its position in Medgenics Inc (NASDAQ:GNMX) by 515.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 93,600 shares of the biotechnology company’s stock after purchasing an additional 78,400 shares during the period. Renaissance Technologies LLC owned approximately 0.16% of Medgenics worth $112,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 20.44% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/fy2019-eps-estimates-for-medgenics-inc-gnmx-cut-by-analyst.html.
Medgenics Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn's disease.
Get a free copy of the Zacks research report on Medgenics (GNMX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.